{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:33:24Z","timestamp":1771378404183,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302841"],"award-info":[{"award-number":["81302841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Outstanding Talent Support Plan Foundation of Liaoning Province","award":["LJQ2014086"],"award-info":[{"award-number":["LJQ2014086"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00404-020-05865-z","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T19:02:30Z","timestamp":1605985350000},"page":"285-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"303","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-2357","authenticated-orcid":false,"given":"Chongzhen","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2546-5720","authenticated-orcid":false,"given":"Chengda","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianyue","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-1856","authenticated-orcid":false,"given":"Rongrong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6273-2704","authenticated-orcid":false,"given":"Jianyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"issue":"1","key":"5865_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"L Siegel Rebecca","year":"2020","unstructured":"Siegel Rebecca L, Miller Kimberly D (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"5865_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"5865_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1758834014544121","volume":"6","author":"D Luvero","year":"2014","unstructured":"Luvero D, Milani A, Ledermann JA (2014) Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6(5):229\u2013239. https:\/\/doi.org\/10.1177\/1758834014544121","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"5865_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cells8091102","volume":"8","author":"J J\u00e1szai","year":"2019","unstructured":"J\u00e1szai J, Schmidt MHH (2019) Trends and challenges in tumor anti-angiogenic therapies. Cells 8(9):1102. https:\/\/doi.org\/10.3390\/cells8091102","journal-title":"Cells"},{"issue":"2","key":"5865_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/thno.21674","volume":"8","author":"AME Abdalla","year":"2018","unstructured":"Abdalla AME, Xiao L, Ullah MW, Yu M, Ouyang C, Yang G (2018) Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics. Theranostics 8(2):533\u2013548. https:\/\/doi.org\/10.7150\/thno.21674","journal-title":"Theranostics"},{"issue":"1","key":"5865_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/jcm9010084","volume":"9","author":"RI Teleanu","year":"2019","unstructured":"Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM (2019) Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med 9(1):84. https:\/\/doi.org\/10.3390\/jcm9010084","journal-title":"J Clin Med"},{"issue":"5","key":"5865_CR7","doi-asserted-by":"publisher","first-page":"E1172","DOI":"10.3390\/cancers12051172","volume":"12","author":"H Saman","year":"2020","unstructured":"Saman H, Raza SS, Uddin S, Rasul K (2020) Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers (Basel) 12(5):E1172. https:\/\/doi.org\/10.3390\/cancers12051172","journal-title":"Cancers (Basel)"},{"key":"5865_CR8","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"5865_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.5506","author":"S Pignata","year":"2018","unstructured":"Pignata S, Lorusso D, Joly F et al (2018) Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5506","journal-title":"J Clin Oncol"},{"key":"5865_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.5506","author":"JA Ledermann","year":"2017","unstructured":"Ledermann JA, Embleton AC, Perren T et al (2017) Overall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.5506","journal-title":"J Clin Oncol"},{"issue":"1","key":"5865_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV (2015) Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139(1):10\u201316. https:\/\/doi.org\/10.1016\/j.ygyno.2015.08.004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"5865_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","volume":"13","author":"WH Gotlieb","year":"2012","unstructured":"Gotlieb WH, Amant F, Advani S et al (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13(2):154\u2013162. https:\/\/doi.org\/10.1016\/S1470-2045(11)70338-2","journal-title":"Lancet Oncol"},{"issue":"4","key":"5865_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","volume":"30","author":"BY Karlan","year":"2012","unstructured":"Karlan BY, Oza AM, Richardson GE et al (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362\u2013371. https:\/\/doi.org\/10.1200\/JCO.2010.34.3178","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"5865_CR14","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/S0049-3848(10)70014-1","volume":"125","author":"F Elice","year":"2010","unstructured":"Elice F, Rodeghiero F (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res 125(Suppl 2):S55\u2013S57. https:\/\/doi.org\/10.1016\/S0049-3848(10)70014-1","journal-title":"Thromb Res"},{"issue":"34","key":"5865_CR15","doi-asserted-by":"publisher","first-page":"e11920","DOI":"10.1097\/MD.0000000000011920","volume":"97","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Sun X, Kong B, Jiang J (2018) Antiangiogenesis therapy in ovarian cancer patients: an updated meta-analysis for 15 randomized controlled trials. Medicine (Baltimore) 97(34):e11920. https:\/\/doi.org\/10.1097\/MD.0000000000011920","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"5865_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","volume":"32","author":"IB Vergote","year":"2014","unstructured":"Vergote IB, Jimeno A, Joly F et al (2014) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 32(4):320\u2013326. https:\/\/doi.org\/10.1200\/JCO.2013.50.5669","journal-title":"J Clin Oncol"},{"issue":"5","key":"5865_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672\u2013705. https:\/\/doi.org\/10.1093\/annonc\/mdz062","journal-title":"Ann Oncol"},{"key":"5865_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.5518","author":"I Vergote","year":"2018","unstructured":"Vergote I, Hanker LC, Floquet A et al (2018) AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer\u2014Overall survival (OS) results. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5518","journal-title":"J Clin Oncol"},{"issue":"3","key":"5865_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-019-00347-4","volume":"33","author":"SA Cook","year":"2019","unstructured":"Cook SA, Tinker AV (2019) PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs 33(3):255\u2013273. https:\/\/doi.org\/10.1007\/s40259-019-00347-4","journal-title":"BioDrugs"},{"issue":"4","key":"5865_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/annonc\/mdz018","volume":"30","author":"JF Liu","year":"2019","unstructured":"Liu JF, Barry WT, Birrer M et al (2019) Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 30(4):551\u2013557. https:\/\/doi.org\/10.1093\/annonc\/mdz018","journal-title":"Ann Oncol"},{"issue":"25","key":"5865_CR21","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"issue":"10043","key":"5865_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388(10043):518\u2013529. https:\/\/doi.org\/10.1016\/S0140-6736(15)01088-0","journal-title":"Lancet"},{"key":"5865_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx066","author":"C Bais","year":"2017","unstructured":"Bais C, Mueller B, Brady MF et al (2017) Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx066","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"5865_CR24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-19-0226","volume":"26","author":"AA Secord","year":"2020","unstructured":"Secord AA, Burdett KB, Owzar K et al (2020) Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: results from GOG-0218. Clin Cancer Res 26(6):1288\u20131296. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0226","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5865_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/annonc\/mdx796","volume":"29","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Rau J, Lee CK et al (2018) Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. Ann Oncol 29(3):737\u2013743. https:\/\/doi.org\/10.1093\/annonc\/mdx796","journal-title":"Ann Oncol"},{"issue":"3","key":"5865_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","volume":"14","author":"D Stark","year":"2013","unstructured":"Stark D, Nankivell M, Pujade-Lauraine E et al (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14(3):236\u2013243. https:\/\/doi.org\/10.1016\/S1470-2045(12)70567-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"5865_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","volume":"153","author":"M Gore","year":"2019","unstructured":"Gore M, Hackshaw A, Brady WE et al (2019) An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol 153(3):541\u2013548. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.256","journal-title":"Gynecol Oncol"},{"issue":"26","key":"5865_CR28","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D et al (2019) Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37(26):2317\u20132328. https:\/\/doi.org\/10.1200\/JCO.19.01009","journal-title":"J Clin Oncol"},{"issue":"6","key":"5865_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18(6):779\u2013791. https:\/\/doi.org\/10.1016\/S1470-2045(17)30279-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"5865_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16(8):928\u2013936. https:\/\/doi.org\/10.1016\/S1470-2045(15)00086-8","journal-title":"Lancet Oncol"},{"issue":"13","key":"5865_CR31","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302\u20131308. https:\/\/doi.org\/10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol"},{"issue":"1","key":"5865_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000602","volume":"28","author":"JW Kim","year":"2018","unstructured":"Kim JW, Mahner S, Wu LY et al (2018) Pazopanib maintenance therapy in east Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer 28(1):2\u201310. https:\/\/doi.org\/10.1097\/IGC.0000000000000602","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"5865_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","volume":"4","author":"DL Richardson","year":"2018","unstructured":"Richardson DL, Sill MW, Coleman RL et al (2018) Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol 4(2):196\u2013202. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4218","journal-title":"JAMA Oncol"},{"issue":"5","key":"5865_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","volume":"16","author":"S Pignata","year":"2015","unstructured":"Pignata S, Lorusso D, Scambia G et al (2015) Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol 16(5):561\u2013568. https:\/\/doi.org\/10.1016\/S1470-2045(15)70115-4","journal-title":"Lancet Oncol"},{"issue":"2","key":"5865_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ijc.32606","volume":"146","author":"I Ray-Coquard","year":"2020","unstructured":"Ray-Coquard I, Cibula D, Mirza MR et al (2020) Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer 146(2):439\u2013448. https:\/\/doi.org\/10.1002\/ijc.32606","journal-title":"Int J Cancer"},{"issue":"28","key":"5865_CR36","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","volume":"29","author":"JA Ledermann","year":"2011","unstructured":"Ledermann JA, Hackshaw A, Kaye S et al (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29(28):3798\u20133804. https:\/\/doi.org\/10.1200\/JCO.2010.33.5208","journal-title":"J Clin Oncol"},{"issue":"9","key":"5865_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","volume":"19","author":"R Chekerov","year":"2018","unstructured":"Chekerov R, Hilpert F, Mahner S et al (2018) Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 19(9):1247\u20131258. https:\/\/doi.org\/10.1016\/S1470-2045(18)30372-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"5865_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","volume":"130","author":"TJ Herzog","year":"2013","unstructured":"Herzog TJ, Scambia G, Kim BG et al (2013) A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 130(1):25\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.011","journal-title":"Gynecol Oncol"},{"issue":"6","key":"5865_CR39","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","volume":"20","author":"I Vergote","year":"2019","unstructured":"Vergote I, Scambia G, O\u2019Malley DM et al (2019) Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol 20(6):862\u2013876. https:\/\/doi.org\/10.1016\/S1470-2045(19)30178-0","journal-title":"Lancet Oncol"},{"key":"5865_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2016.09.004","volume":"70","author":"C Marth","year":"2017","unstructured":"Marth C, Vergote I, Scambia G et al (2017) ENGOT-ov-6\/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer 70:111\u2013121. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.004","journal-title":"Eur J Cancer"},{"issue":"1","key":"5865_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","volume":"143","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Poveda A, Vergote I et al (2016) Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol 143(1):27\u201334. https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.112","journal-title":"Gynecol Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05865-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05865-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05865-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T11:50:37Z","timestamp":1612353037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05865-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5865"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05865-z","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"10 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}